Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 338

1.

Bilingualism as a Contributor to Cognitive Reserve? Evidence from Cerebral Glucose Metabolism in Mild Cognitive Impairment and Alzheimer's Disease.

Kowoll ME, Degen C, Gorenc L, Küntzelmann A, Fellhauer I, Giesel F, Haberkorn U, Schröder J.

Front Psychiatry. 2016 Apr 15;7:62. doi: 10.3389/fpsyt.2016.00062. eCollection 2016.

2.

A liposomal formulation for the oral application of the investigational hepatitis B drug Myrcludex B.

Uhl P, Helm F, Hofhaus G, Brings S, Kaufman C, Leotta K, Urban S, Haberkorn U, Mier W, Fricker G.

Eur J Pharm Biopharm. 2016 Jun;103:159-66. doi: 10.1016/j.ejpb.2016.03.031. Epub 2016 Apr 2.

PMID:
27049970
3.

Semi-automatic 3D-volumetry of liver metastases from neuroendocrine tumors to improve combination therapy with 177Lu-DOTATOC and 90Y-DOTATOC.

Cieciera M, Kratochwil C, Moltz J, Kauczor HU, Holland Letz T, Choyke P, Mier W, Haberkorn U, Giesel FL.

Diagn Interv Radiol. 2016 May-Jun;22(3):201-6. doi: 10.5152/dir.2015.15304.

4.

Renal Targeting: Peptide-Based Drug Delivery to Proximal Tubule Cells.

Wischnjow A, Sarko D, Janzer M, Kaufman C, Beijer B, Brings S, Haberkorn U, Larbig G, Kübelbeck A, Mier W.

Bioconjug Chem. 2016 Apr 20;27(4):1050-7. doi: 10.1021/acs.bioconjchem.6b00057. Epub 2016 Mar 30.

PMID:
26999755
5.

PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with Lu-177 labeled PSMA-617.

Kratochwil C, Giesel FL, Stefanova M, Benešová M, Bronzel M, Afshar-Oromieh A, Mier W, Eder M, Kopka K, Haberkorn U.

J Nucl Med. 2016 Mar 16. pii: jnumed.115.171397. [Epub ahead of print]

PMID:
26985056
6.

Intra-individual comparison of 68Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer.

Giesel FL, Sterzing F, Schlemmer HP, Holland-Letz T, Mier W, Rius M, Afshar-Oromieh A, Kopka K, Debus J, Haberkorn U, Kratochwil C.

Eur J Nucl Med Mol Imaging. 2016 Mar 14. [Epub ahead of print]

PMID:
26971788
7.

Linker Modification Strategies To Control the Prostate-Specific Membrane Antigen (PSMA)-Targeting and Pharmacokinetic Properties of DOTA-Conjugated PSMA Inhibitors.

Benešová M, Bauder-Wüst U, Schäfer M, Klika KD, Mier W, Haberkorn U, Kopka K, Eder M.

J Med Chem. 2016 Mar 10;59(5):1761-75. doi: 10.1021/acs.jmedchem.5b01210. Epub 2016 Mar 1.

PMID:
26878194
8.

(68)Ga-PSMA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancer.

Sachpekidis C, Eder M, Kopka K, Mier W, Hadaschik BA, Haberkorn U, Dimitrakopoulou-Strauss A.

Eur J Nucl Med Mol Imaging. 2016 Jul;43(7):1288-99. doi: 10.1007/s00259-015-3302-4. Epub 2016 Jan 12.

PMID:
26753602
9.

New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy.

Haberkorn U, Eder M, Kopka K, Babich JW, Eisenhut M.

Clin Cancer Res. 2016 Jan 1;22(1):9-15. doi: 10.1158/1078-0432.CCR-15-0820.

PMID:
26728408
10.

Novel Bispecific PSMA/GRPr Targeting Radioligands with Optimized Pharmacokinetics for Improved PET Imaging of Prostate Cancer.

Liolios C, Schäfer M, Haberkorn U, Eder M, Kopka K.

Bioconjug Chem. 2016 Mar 16;27(3):737-51. doi: 10.1021/acs.bioconjchem.5b00687. Epub 2016 Jan 25.

PMID:
26726823
11.

Increased x-ray attenuation in malignant vs. benign mediastinal nodes in an orthotopic model of lung cancer.

Flechsig P, Choyke P, Kratochwil C, Warth A, Antoch G, Holland Letz T, Rath D, Eichwald V, Huber PE, Kauczor HU, Haberkorn U, Giesel FL.

Diagn Interv Radiol. 2016 Jan-Feb;22(1):35-9. doi: 10.5152/dir.2015.15220.

12.

Application of (18)F-FDG PET and diffusion weighted imaging (DWI) in multiple myeloma: comparison of functional imaging modalities.

Sachpekidis C, Mosebach J, Freitag MT, Wilhelm T, Mai EK, Goldschmidt H, Haberkorn U, Schlemmer HP, Delorme S, Dimitrakopoulou-Strauss A.

Am J Nucl Med Mol Imaging. 2015 Oct 12;5(5):479-92. eCollection 2015.

13.

Comparison of (18)F-FDG PET/CT and PET/MRI in patients with multiple myeloma.

Sachpekidis C, Hillengass J, Goldschmidt H, Mosebach J, Pan L, Schlemmer HP, Haberkorn U, Dimitrakopoulou-Strauss A.

Am J Nucl Med Mol Imaging. 2015 Oct 12;5(5):469-78. eCollection 2015.

14.

Comparison of hybrid (68)Ga-PSMA PET/MRI and (68)Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer.

Freitag MT, Radtke JP, Hadaschik BA, Kopp-Schneider A, Eder M, Kopka K, Haberkorn U, Roethke M, Schlemmer HP, Afshar-Oromieh A.

Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):70-83. doi: 10.1007/s00259-015-3206-3. Epub 2015 Oct 28.

PMID:
26508290
15.

Inhibition of Fatty Acid Synthase Sensitizes Prostate Cancer Cells to Radiotherapy.

Rae C, Haberkorn U, Babich JW, Mairs RJ.

Radiat Res. 2015 Nov;184(5):482-93. doi: 10.1667/RR14173.1. Epub 2015 Oct 20.

PMID:
26484401
16.

(68)Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients.

Sterzing F, Kratochwil C, Fiedler H, Katayama S, Habl G, Kopka K, Afshar-Oromieh A, Debus J, Haberkorn U, Giesel FL.

Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):34-41. doi: 10.1007/s00259-015-3188-1. Epub 2015 Sep 25.

17.

Positron Emission Tomography-computed Tomography with Prostate-specific Membrane Antigen Ligands as a Promising Tool for Imaging of Prostate Cancer.

Haberkorn U, Kopka K, Hadaschik B.

Eur Urol. 2016 Mar;69(3):397-9. doi: 10.1016/j.eururo.2015.08.059. Epub 2015 Sep 14. No abstract available.

PMID:
26382086
18.

High treatment efficacy by dual targeting of Burkitt's lymphoma xenografted mice with a (177)Lu-based CD22-specific radioimmunoconjugate and rituximab.

Weber T, Bötticher B, Mier W, Sauter M, Krämer S, Leotta K, Keller A, Schlegelmilch A, Grosse-Hovest L, Jäger D, Haberkorn U, Arndt MA, Krauss J.

Eur J Nucl Med Mol Imaging. 2016 Mar;43(3):489-98. doi: 10.1007/s00259-015-3175-6. Epub 2015 Sep 4.

PMID:
26341366
19.

A Comparison of microCT and microPET for Evaluating Lymph Node Metastasis in a Rat Model.

Flechsig P, Kratochwil C, Warth A, Rath D, Eichwald V, Huber PE, Kauczor HU, Haberkorn U, Giesel FL.

Mol Imaging Biol. 2016 Apr;18(2):243-8. doi: 10.1007/s11307-015-0890-0.

PMID:
26330160
20.

Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer.

Delker A, Fendler WP, Kratochwil C, Brunegraf A, Gosewisch A, Gildehaus FJ, Tritschler S, Stief CG, Kopka K, Haberkorn U, Bartenstein P, Böning G.

Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):42-51. doi: 10.1007/s00259-015-3174-7. Epub 2015 Aug 29.

PMID:
26318602
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk